Half-dose verteporfin therapy for central serous chorioretinopathy
Author Information
Author(s): Ng Winnie WK, Wu Zenith HY, Lai Timothy YY
Primary Institution: Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, The Chinese University of Hong Kong, Hong Kong
Hypothesis
Can half-dose verteporfin photodynamic therapy effectively treat bullous retinal detachment in central serous chorioretinopathy?
Conclusion
Half-dose verteporfin photodynamic therapy is an effective treatment option for bullous retinal detachment caused by central serous chorioretinopathy.
Supporting Evidence
- The patient's vision improved from 20/70 to 20/25 within one month of treatment.
- Complete resolution of sub-retinal fluid and bullous retinal detachment was observed three months after treatment.
- There was no recurrence of central serous chorioretinopathy noted in three years of follow-up.
Takeaway
A man with vision problems due to a specific eye condition got better after receiving a lower dose of a special light treatment.
Methodology
The patient was treated with half-dose verteporfin photodynamic therapy after failing to improve with observation and medication.
Limitations
The long-term complications and recurrence rate of half-dose treatment remain unknown.
Participant Demographics
51-year-old Chinese man
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website